MedPath
Found 5 clinical trials|View Analysis
Sort by:

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

First Posted Date
2024-02-13
Last Posted Date
2024-02-13
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
200
Registration Number
NCT06255392
Locations
🇨🇳

Sun Yat Sen Memorial Hospital,Sun Yat sen University, Guangzhou, Guangdong, China

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1
Recruiting
Conditions
Recurrent Breast Cancer
Metastatic Breast Cancer
Advanced Malignancies
Interventions
First Posted Date
2024-01-11
Last Posted Date
2024-03-12
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
154
Registration Number
NCT06202261
Locations
🇨🇳

Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China

🇨🇳

Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

First Posted Date
2023-10-12
Last Posted Date
2023-10-12
Lead Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Target Recruit Count
400
Registration Number
NCT06079983
Locations
🇨🇳

Jilin Provincial Cancer Hospital, Changchun, China

🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, China

🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

and more 47 locations

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

Phase 2
Recruiting
Conditions
HER2-positive Breast Cancer
Interventions
First Posted Date
2023-07-14
Last Posted Date
2023-07-14
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
78
Registration Number
NCT05945368
Locations
🇨🇳

LI YuDong, Guanzhou, Guangdong, China

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

First Posted Date
2020-11-23
Last Posted Date
2024-06-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
331
Registration Number
NCT04639986
Locations
🇨🇳

Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China

🇰🇷

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 40 locations
© Copyright 2025. All Rights Reserved by MedPath